{"transactions":[{"id":721198,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-07-01T20:30:40.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":1905,"price":11.15,"value":21240.75,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan (\"ESPP\"), for the ESPP purchase period of January 1, 2026 through June 30, 2026.  This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026."}],"balance_after":461425,"source":{"system":"sec-edgar","filing":"0001822879-26-000006","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000182287926000006/primarydocument.xml","form_type":"4"}},{"id":747913,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-06-05T20:28:00.000Z","date":"2026-06-04","kind":"sale","planned":false,"acquired":false,"shares":34273,"price":17.9335,"value":614634.8455,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $17.665 USD to $18.37 USD; the price reported above reflects the weighted average sale price."}],"balance_after":459520,"source":{"system":"sec-edgar","filing":"0001822879-26-000004","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000182287926000004/primarydocument.xml","form_type":"4"}},{"id":858318,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-05T21:31:35.000Z","date":"2026-03-03","kind":"grant","planned":false,"acquired":true,"shares":216388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date."}],"balance_after":216388,"derivative":{"exercise_price":13.3,"expiration_date":"2036-03-03","underlying":"Ordinary Shares","underlying_shares":216388},"source":{"system":"sec-edgar","filing":"0001822879-26-000003","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000182287926000003/primarydocument.xml","form_type":"4"}},{"id":858317,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-03-05T21:31:35.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":5607,"price":13.3054,"value":74603.3778,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price."}],"balance_after":493793,"source":{"system":"sec-edgar","filing":"0001822879-26-000003","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000182287926000003/primarydocument.xml","form_type":"4"}},{"id":858316,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-03-05T21:31:35.000Z","date":"2026-03-03","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents restricted share units that are scheduled to vest in equal  parts on the first, second and third  anniversary of the grant date, subject to the reporting person's continued employment through such dates."}],"balance_after":499400,"source":{"system":"sec-edgar","filing":"0001822879-26-000003","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000182287926000003/primarydocument.xml","form_type":"4"}},{"id":867066,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-03-03T21:09:33.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":7232,"price":13.493,"value":97581.376,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $13.3126 USD to $13.70 USD; the price reported above reflects the weighted average sale price."}],"balance_after":349400,"source":{"system":"sec-edgar","filing":"0001822879-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000182287926000002/primarydocument.xml","form_type":"4"}},{"id":867065,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-03-03T21:09:33.000Z","date":"2026-02-28","kind":"grant","planned":false,"acquired":true,"shares":18621,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Represents vesting of performance-based restricted stock units."}],"balance_after":356632,"source":{"system":"sec-edgar","filing":"0001822879-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000182287926000002/primarydocument.xml","form_type":"4"}},{"id":867064,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-03-03T21:09:33.000Z","date":"2026-02-27","kind":"sale","planned":false,"acquired":false,"shares":9734,"price":13.6638,"value":133003.4292,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $13.45 USD to $13.97 USD; the price reported above reflects the weighted average sale price."}],"balance_after":338011,"source":{"system":"sec-edgar","filing":"0001822879-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000182287926000002/primarydocument.xml","form_type":"4"}},{"id":1008127,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pres., Novocure Oncology"}}],"security":"Ordinary Shares","published_at":"2025-11-04T21:09:29.000Z","date":"2025-11-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":966,"price":12.81,"value":12374.46,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1)."}],"balance_after":347745,"source":{"system":"sec-edgar","filing":"0001822879-25-000006","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000182287925000006/primarydocument.xml","form_type":"4"}},{"id":1097823,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pres., Novocure Oncology"}}],"security":"Ordinary Shares","published_at":"2025-07-01T20:19:49.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":833,"price":15.13,"value":12603.29,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan (\"ESPP\"), for the ESPP purchase period of January 1, 2025 through June 30, 2025.  This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2025."}],"balance_after":348711,"source":{"system":"sec-edgar","filing":"0001562180-25-005188","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218025005188/primarydocument.xml","form_type":"4"}},{"id":1119602,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pres., Novocure Oncology"}}],"security":"Ordinary Shares","published_at":"2025-06-06T20:10:42.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":179426,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents restricted share units that are scheduled to vest in equal installments on June 4, 2026 and 2027, subject to the reporting person's continued employment through such dates."}],"balance_after":347878,"source":{"system":"sec-edgar","filing":"0001562180-25-004553","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218025004553/primarydocument.xml","form_type":"4"}},{"id":1122875,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pres., Novocure Oncology"}}],"security":"Ordinary Shares","published_at":"2025-06-04T20:09:33.000Z","date":"2025-06-02","kind":"sale","planned":true,"acquired":false,"shares":1879,"price":19.0111,"value":35721.8569,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On the transaction date, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, the reporting person sold 1,879 shares in multiple trades at prices ranging from $18.78 to $19.03.  The price reported above reflects the weighted average sale price.  The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":168452,"source":{"system":"sec-edgar","filing":"0001562180-25-004426","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218025004426/primarydocument.xml","form_type":"4"}},{"id":1122874,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pres., Novocure Oncology"}}],"security":"Ordinary Shares","published_at":"2025-06-04T20:09:33.000Z","date":"2025-06-02","kind":"sale","planned":true,"acquired":false,"shares":6600,"price":17.9898,"value":118732.68,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On the transaction date, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, the reporting person sold 6,600 shares in multiple trades at prices ranging from $17.71 to $18.65.  The price reported above reflects the weighted average sale price.  The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":170331,"source":{"system":"sec-edgar","filing":"0001562180-25-004426","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218025004426/primarydocument.xml","form_type":"4"}},{"id":1122873,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pres., Novocure Oncology"}}],"security":"Ordinary Shares","published_at":"2025-06-04T20:09:33.000Z","date":"2025-06-02","kind":"sale","planned":true,"acquired":false,"shares":21717,"price":17.2196,"value":373958.0532,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On the transaction date, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, the reporting person sold 21,717 shares in multiple trades at prices ranging from $16.71 to $17.70.  The price reported above reflects the weighted average sale price.  The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":176931,"source":{"system":"sec-edgar","filing":"0001562180-25-004426","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218025004426/primarydocument.xml","form_type":"4"}},{"id":1219527,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pres., Novocure Oncology"}}],"security":"Stock Options (Right to buy)","published_at":"2025-03-06T21:41:11.000Z","date":"2025-03-04","kind":"grant","planned":false,"acquired":true,"shares":81499,"price":18.19,"value":1482466.81,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Options to buy 81,499 ordinary shares will vest in equal installments on each of March 4, 2026, 2027, 2028 and 2029, subject to the reporting person's continued employment through such dates."}],"balance_after":81499,"derivative":{"exercise_price":18.19,"exercise_date":"2026-03-04","expiration_date":"2035-03-03","underlying":"Ordinary Shares","underlying_shares":81499},"source":{"system":"sec-edgar","filing":"0001562180-25-002159","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218025002159/primarydocument.xml","form_type":"4"}},{"id":1219526,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pres., Novocure Oncology"}}],"security":"Ordinary Shares","published_at":"2025-03-06T21:41:11.000Z","date":"2025-03-04","kind":"grant","planned":false,"acquired":true,"shares":54975,"price":18.19,"value":999995.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted share units that are scheduled to vest in equal installments on March 4, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates."}],"balance_after":198648,"source":{"system":"sec-edgar","filing":"0001562180-25-002159","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218025002159/primarydocument.xml","form_type":"4"}},{"id":1228363,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pres., Novocure Oncology"}}],"security":"Ordinary Shares","published_at":"2025-03-04T21:19:12.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":2527,"price":18.5363,"value":46841.2301,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On the transaction date, the reporting person sold 2,527 shares in multiple trades at prices ranging from $18.02 to $18.9918.  The price reported above reflects the weighted average sale price.  The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":143673,"source":{"system":"sec-edgar","filing":"0001562180-25-001976","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218025001976/primarydocument.xml","form_type":"4"}},{"id":1235738,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pres., Novocure Oncology"}}],"security":"Ordinary Shares","published_at":"2025-03-04T02:26:33.000Z","date":"2025-02-28","kind":"sale","planned":false,"acquired":false,"shares":2770,"price":18.2843,"value":50647.511,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On February 28, 2025, the reporting person sold 2,770 shares in multiple trades at prices ranging from $18.175 to $18.765.  The price reported above reflects the weighted average sale price.  The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":146200,"source":{"system":"sec-edgar","filing":"0001562180-25-001915","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218025001915/primarydocument.xml","form_type":"4/A","original_submission_date":"2025-03-03"}},{"id":1235737,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pres., Novocure Oncology"}}],"security":"Ordinary Shares","published_at":"2025-03-04T02:26:33.000Z","date":"2025-02-27","kind":"sale","planned":false,"acquired":false,"shares":1989,"price":20.549,"value":40871.961,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 27, 2025, the reporting person sold 1,989 shares in multiple trades at prices ranging from $20.41 to $20.85.  The price reported above reflects the weighted average sale price.  The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":148970,"source":{"system":"sec-edgar","filing":"0001562180-25-001915","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218025001915/primarydocument.xml","form_type":"4/A","original_submission_date":"2025-03-03"}},{"id":1235736,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pres., Novocure Oncology"}}],"security":"Ordinary Shares","published_at":"2025-03-04T02:26:33.000Z","date":"2025-02-27","kind":"sale","planned":false,"acquired":false,"shares":10277,"price":19.9219,"value":204737.3663,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 27, 2025, the reporting person sold 10,277 shares in multiple trades at prices ranging from $19.41 to $20.4033.  The price reported above reflects the weighted average sale price.  The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":150959,"source":{"system":"sec-edgar","filing":"0001562180-25-001915","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218025001915/primarydocument.xml","form_type":"4/A","original_submission_date":"2025-03-03"}},{"id":1235727,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pres., Novocure Oncology"}}],"security":"Ordinary Shares","published_at":"2025-03-03T21:27:32.000Z","date":"2025-02-28","kind":"sale","planned":false,"acquired":false,"shares":2770,"price":18.2843,"value":50647.511,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 28, 2025, the reporting person sold 2,770 shares in multiple trades at prices ranging from $18.175 to $18.765. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":146200,"source":{"system":"sec-edgar","filing":"0001562180-25-001834","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218025001834/primarydocument.xml","form_type":"4"}},{"id":1235726,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pres., Novocure Oncology"}}],"security":"Ordinary Shares","published_at":"2025-03-03T21:27:32.000Z","date":"2025-02-27","kind":"sale","planned":false,"acquired":false,"shares":1989,"price":20.549,"value":40871.961,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 27, 2025, the reporting person sold 1,989 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":148970,"source":{"system":"sec-edgar","filing":"0001562180-25-001834","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218025001834/primarydocument.xml","form_type":"4"}},{"id":1235725,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pres., Novocure Oncology"}}],"security":"Ordinary Shares","published_at":"2025-03-03T21:27:32.000Z","date":"2025-02-27","kind":"sale","planned":false,"acquired":false,"shares":10277,"price":19.9219,"value":204737.3663,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 27, 2025, the reporting person sold 10,277 shares in multiple trades at prices ranging from $19.41 to $20.4033.  The price reported above reflects the weighted average sale price.  The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":150959,"source":{"system":"sec-edgar","filing":"0001562180-25-001834","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218025001834/primarydocument.xml","form_type":"4"}},{"id":1377132,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pres., Novocure Oncology"}}],"security":"Ordinary Shares","published_at":"2024-11-04T21:34:12.000Z","date":"2024-11-01","kind":"sale","planned":false,"acquired":false,"shares":598,"price":15.9377,"value":9530.7446,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $15.88 USD to $15.9603 USD; the price reported above reflects the weighted average sale price."}],"balance_after":161236,"source":{"system":"sec-edgar","filing":"0001562180-24-007516","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218024007516/primarydocument.xml","form_type":"4"}},{"id":1439622,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pres., Novocure Oncology"}}],"security":"Ordinary Shares","published_at":"2024-08-06T20:17:56.000Z","date":"2024-06-28","kind":"grant","planned":false,"acquired":true,"shares":1736,"price":12.24,"value":21248.64,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan (\"ESPP\"), for the ESPP purchase period of January 1, 2024 through June 30, 2024.  This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2024."}],"balance_after":161834,"source":{"system":"sec-edgar","filing":"0001562180-24-006039","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218024006039/primarydocument.xml","form_type":"4"}},{"id":1596148,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pres., Novocure Oncology"}}],"security":"Ordinary Shares","published_at":"2024-03-05T21:08:02.000Z","date":"2024-03-04","kind":"sale","planned":false,"acquired":false,"shares":840,"price":16.01,"value":13448.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":160098,"source":{"system":"sec-edgar","filing":"0001562180-24-002247","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218024002247/primarydocument.xml","form_type":"4"}},{"id":1596147,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pres., Novocure Oncology"}}],"security":"Ordinary Shares","published_at":"2024-03-05T21:08:02.000Z","date":"2024-03-01","kind":"sale","planned":false,"acquired":false,"shares":1679,"price":16.0269,"value":26909.1651,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":160938,"source":{"system":"sec-edgar","filing":"0001562180-24-002247","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218024002247/primarydocument.xml","form_type":"4"}},{"id":1609996,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pres., Novocure Oncology"}}],"security":"Stock Options (Right to buy)","published_at":"2024-02-29T21:38:56.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":156348,"price":16.3,"value":2548472.4,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Options to buy 156,348 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates."}],"balance_after":156348,"derivative":{"exercise_price":16.3,"exercise_date":"2025-02-27","expiration_date":"2034-02-26","underlying":"Ordinary Shares","underlying_shares":156348},"source":{"system":"sec-edgar","filing":"0001562180-24-001988","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218024001988/primarydocument.xml","form_type":"4"}},{"id":1609995,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pres., Novocure Oncology"}}],"security":"Ordinary Shares","published_at":"2024-02-29T21:38:56.000Z","date":"2024-02-28","kind":"sale","planned":false,"acquired":false,"shares":2078,"price":16.1428,"value":33544.7384,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":162617,"source":{"system":"sec-edgar","filing":"0001562180-24-001988","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218024001988/primarydocument.xml","form_type":"4"}},{"id":1609994,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Pres., Novocure Oncology"}}],"security":"Ordinary Shares","published_at":"2024-02-29T21:38:56.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":102249,"price":16.3,"value":1666658.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates."}],"balance_after":164695,"source":{"system":"sec-edgar","filing":"0001562180-24-001988","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218024001988/primarydocument.xml","form_type":"4"}},{"id":1965780,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2023-03-07T21:52:16.000Z","date":"2023-03-07","kind":"sale","acquired":false,"shares":2315,"price":75.5937,"value":174999.4155,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On the transaction date, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, the reporting person sold 2,315 shares in multiple trades at prices ranging from $75.33 to $75.94.  The price reported above reflects the weighted average sale price.  The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":54284,"source":{"system":"sec-edgar","filing":"0001562180-23-002581","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218023002581/primarydocument.xml","form_type":"4"}},{"id":1965779,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2023-03-07T21:52:16.000Z","date":"2023-03-07","kind":"sale","acquired":false,"shares":6003,"price":74.9968,"value":450205.7904,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On the transaction date, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, the reporting person sold 6,003 shares in multiple trades at prices ranging from $74.33 to $75.32.  The price reported above reflects the weighted average sale price.  The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":56599,"source":{"system":"sec-edgar","filing":"0001562180-23-002581","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218023002581/primarydocument.xml","form_type":"4"}},{"id":1965778,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2023-03-07T21:52:16.000Z","date":"2023-03-03","kind":"sale","acquired":false,"shares":888,"price":76.1594,"value":67629.5472,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":62602,"source":{"system":"sec-edgar","filing":"0001562180-23-002581","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218023002581/primarydocument.xml","form_type":"4"}},{"id":1965777,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2023-03-07T21:52:16.000Z","date":"2023-03-03","kind":"sale","acquired":false,"shares":4403,"price":76.1594,"value":335329.8382,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":63490,"source":{"system":"sec-edgar","filing":"0001562180-23-002581","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218023002581/primarydocument.xml","form_type":"4"}},{"id":1969088,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2023-03-06T21:37:48.000Z","date":"2023-03-03","kind":"sale","acquired":false,"shares":2059,"price":77.6391,"value":159858.9069,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":67893,"source":{"system":"sec-edgar","filing":"0001562180-23-002489","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218023002489/primarydocument.xml","form_type":"4"}},{"id":1969087,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2023-03-06T21:37:48.000Z","date":"2023-03-03","kind":"grant","acquired":true,"shares":11808,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents vesting of performance-based restricted stock units."}],"balance_after":69952,"source":{"system":"sec-edgar","filing":"0001562180-23-002489","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218023002489/primarydocument.xml","form_type":"4"}},{"id":1969086,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2023-03-06T21:37:48.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":844,"price":75.2779,"value":63534.5476,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":58144,"source":{"system":"sec-edgar","filing":"0001562180-23-002489","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218023002489/primarydocument.xml","form_type":"4"}},{"id":1973439,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2023-03-03T21:13:03.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":308,"price":76.0511,"value":23423.7388,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 2, 2023 pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leonard, Mr. Leonard sold 308 shares in multiple trades at prices ranging from $75.95 to $76.14.  The price reported above reflects the weighted average sale price.  Mr. Leonard hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":58988,"source":{"system":"sec-edgar","filing":"0001562180-23-002359","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218023002359/primarydocument.xml","form_type":"4"}},{"id":1973438,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2023-03-03T21:13:03.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":3799,"price":75.3235,"value":286153.9765,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 2, 2023 pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leonard, Mr. Leonard sold 3,799 shares in multiple trades at prices ranging from $74.89 to $75.88.  The price reported above reflects the weighted average sale price.  Mr. Leonard hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":59296,"source":{"system":"sec-edgar","filing":"0001562180-23-002359","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218023002359/primarydocument.xml","form_type":"4"}},{"id":1979492,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Options to Buy Ordinary Shares","published_at":"2023-03-02T22:01:17.000Z","date":"2023-02-28","kind":"grant","acquired":true,"shares":30971,"price":76.97,"value":2383837.87,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Options to buy 30,971 ordinary shares will vest and become exercisable in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates."}],"balance_after":30971,"derivative":{"exercise_price":76.97,"exercise_date":"2024-02-28","expiration_date":"2033-02-27","underlying":"Ordinary Shares","underlying_shares":30971},"source":{"system":"sec-edgar","filing":"0001645113-23-000031","document":"wf-form4_167779444622406.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000031/wf-form4_167779444622406.xml","form_type":"4"}},{"id":1979491,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2023-03-02T22:01:17.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":1684,"price":76.3624,"value":128594.2816,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units.  This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":63095,"source":{"system":"sec-edgar","filing":"0001645113-23-000031","document":"wf-form4_167779444622406.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000031/wf-form4_167779444622406.xml","form_type":"4"}},{"id":1979490,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2023-03-02T22:01:17.000Z","date":"2023-02-28","kind":"grant","acquired":true,"shares":18621,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted share units that are scheduled to vest in equal installments on each of February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates."}],"balance_after":64779,"source":{"system":"sec-edgar","filing":"0001645113-23-000031","document":"wf-form4_167779444622406.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000031/wf-form4_167779444622406.xml","form_type":"4"}},{"id":2058845,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Options to Buy Ordinary Shares","published_at":"2023-01-09T23:21:59.000Z","date":"2023-01-05","kind":"exercise","acquired":false,"shares":7183,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Fully vested as of the date hereof."}],"balance_after":17662,"derivative":{"exercise_price":21.15,"expiration_date":"2028-02-26","underlying":"Ordinary Shares","underlying_shares":7183},"source":{"system":"sec-edgar","filing":"0001645113-23-000009","document":"wf-form4_167330650457668.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000009/wf-form4_167330650457668.xml","form_type":"4"}},{"id":2058844,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Options to Buy Ordinary Shares","published_at":"2023-01-09T23:21:59.000Z","date":"2023-01-05","kind":"exercise","acquired":false,"shares":7183,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Fully vested as of the date hereof."}],"balance_after":10479,"derivative":{"exercise_price":21.15,"expiration_date":"2028-02-26","underlying":"Ordinary Shares","underlying_shares":7183},"source":{"system":"sec-edgar","filing":"0001645113-23-000009","document":"wf-form4_167330650457668.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000009/wf-form4_167330650457668.xml","form_type":"4"}},{"id":2058843,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Options to Buy Ordinary Shares","published_at":"2023-01-09T23:21:59.000Z","date":"2023-01-05","kind":"exercise","acquired":false,"shares":5517,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":7.15,"expiration_date":"2027-02-21","underlying":"Ordinary Shares","underlying_shares":5517},"source":{"system":"sec-edgar","filing":"0001645113-23-000009","document":"wf-form4_167330650457668.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000009/wf-form4_167330650457668.xml","form_type":"4"}},{"id":2058842,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Options to Buy Ordinary Shares","published_at":"2023-01-09T23:21:59.000Z","date":"2023-01-05","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":11.46,"expiration_date":"2026-02-24","underlying":"Ordinary Shares","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001645113-23-000009","document":"wf-form4_167330650457668.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000009/wf-form4_167330650457668.xml","form_type":"4"}},{"id":2058841,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Options to Buy Ordinary Shares","published_at":"2023-01-09T23:21:59.000Z","date":"2023-01-05","kind":"exercise","acquired":false,"shares":7826,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":14.37,"expiration_date":"2025-02-23","underlying":"Ordinary Shares","underlying_shares":7826},"source":{"system":"sec-edgar","filing":"0001645113-23-000009","document":"wf-form4_167330650457668.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000009/wf-form4_167330650457668.xml","form_type":"4"}},{"id":2058840,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2023-01-09T23:21:59.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":7183,"price":120,"value":861960.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."}],"balance_after":46158,"source":{"system":"sec-edgar","filing":"0001645113-23-000009","document":"wf-form4_167330650457668.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000009/wf-form4_167330650457668.xml","form_type":"4"}},{"id":2058839,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2023-01-09T23:21:59.000Z","date":"2023-01-05","kind":"exercise","acquired":true,"shares":7183,"price":21.15,"value":151920.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."}],"balance_after":53341,"source":{"system":"sec-edgar","filing":"0001645113-23-000009","document":"wf-form4_167330650457668.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000009/wf-form4_167330650457668.xml","form_type":"4"}},{"id":2058838,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2023-01-09T23:21:59.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":7183,"price":114.0001,"value":818862.7183,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leonard, Mr. Leonard sold 7,183 shares in multiple trades at prices ranging from $114.00 to $114.03.  The price reported above reflects the weighted average sale price.  Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":46158,"source":{"system":"sec-edgar","filing":"0001645113-23-000009","document":"wf-form4_167330650457668.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000009/wf-form4_167330650457668.xml","form_type":"4"}},{"id":2058837,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2023-01-09T23:21:59.000Z","date":"2023-01-05","kind":"exercise","acquired":true,"shares":7183,"price":21.15,"value":151920.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."}],"balance_after":53341,"source":{"system":"sec-edgar","filing":"0001645113-23-000009","document":"wf-form4_167330650457668.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000009/wf-form4_167330650457668.xml","form_type":"4"}},{"id":2058836,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2023-01-09T23:21:59.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":5517,"price":108,"value":595836.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."}],"balance_after":46158,"source":{"system":"sec-edgar","filing":"0001645113-23-000009","document":"wf-form4_167330650457668.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000009/wf-form4_167330650457668.xml","form_type":"4"}},{"id":2058835,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2023-01-09T23:21:59.000Z","date":"2023-01-05","kind":"exercise","acquired":true,"shares":5517,"price":7.15,"value":39446.55,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."}],"balance_after":51675,"source":{"system":"sec-edgar","filing":"0001645113-23-000009","document":"wf-form4_167330650457668.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000009/wf-form4_167330650457668.xml","form_type":"4"}},{"id":2058834,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2023-01-09T23:21:59.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":7500,"price":108,"value":810000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."}],"balance_after":46158,"source":{"system":"sec-edgar","filing":"0001645113-23-000009","document":"wf-form4_167330650457668.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000009/wf-form4_167330650457668.xml","form_type":"4"}},{"id":2058833,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2023-01-09T23:21:59.000Z","date":"2023-01-05","kind":"exercise","acquired":true,"shares":7500,"price":11.46,"value":85950.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."}],"balance_after":53658,"source":{"system":"sec-edgar","filing":"0001645113-23-000009","document":"wf-form4_167330650457668.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000009/wf-form4_167330650457668.xml","form_type":"4"}},{"id":2058832,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2023-01-09T23:21:59.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":7826,"price":108,"value":845208.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."}],"balance_after":46158,"source":{"system":"sec-edgar","filing":"0001645113-23-000009","document":"wf-form4_167330650457668.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000009/wf-form4_167330650457668.xml","form_type":"4"}},{"id":2058831,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2023-01-09T23:21:59.000Z","date":"2023-01-05","kind":"exercise","acquired":true,"shares":7826,"price":14.37,"value":112459.62,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."}],"balance_after":53984,"source":{"system":"sec-edgar","filing":"0001645113-23-000009","document":"wf-form4_167330650457668.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000009/wf-form4_167330650457668.xml","form_type":"4"}},{"id":2058830,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2023-01-09T23:21:59.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":1010,"price":117,"value":118170.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."}],"balance_after":46158,"source":{"system":"sec-edgar","filing":"0001645113-23-000009","document":"wf-form4_167330650457668.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000009/wf-form4_167330650457668.xml","form_type":"4"}},{"id":2058829,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2023-01-09T23:21:59.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":526,"price":115.0348,"value":60508.3048,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leonard, Mr. Leonard sold 526 shares in multiple trades at prices ranging from $115.00 to $115.59.  The price reported above reflects the weighted average sale price.  Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":47168,"source":{"system":"sec-edgar","filing":"0001645113-23-000009","document":"wf-form4_167330650457668.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000009/wf-form4_167330650457668.xml","form_type":"4"}},{"id":2058828,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2023-01-09T23:21:59.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":417,"price":108,"value":45036.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."}],"balance_after":47694,"source":{"system":"sec-edgar","filing":"0001645113-23-000009","document":"wf-form4_167330650457668.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000009/wf-form4_167330650457668.xml","form_type":"4"}},{"id":2058827,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2023-01-09T23:21:59.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":2345,"price":119.0077,"value":279073.0565,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leonard, Mr. Leonard sold 2,345 shares in multiple trades at prices ranging from $119.00 to $119.07.  The price reported above reflects the weighted average sale price.  Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":48111,"source":{"system":"sec-edgar","filing":"0001645113-23-000009","document":"wf-form4_167330650457668.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000009/wf-form4_167330650457668.xml","form_type":"4"}},{"id":2125610,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Options to Buy Ordinary Shares","published_at":"2022-11-03T20:42:24.000Z","date":"2022-11-01","kind":"grant","acquired":true,"shares":11609,"price":73.2,"value":849778.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Options to buy 11,609 ordinary shares will vest and become exercisable in equal installments on each of November 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates."}],"balance_after":11609,"derivative":{"exercise_price":73.2,"exercise_date":"2023-11-01","expiration_date":"2032-10-31","underlying":"Ordinary Shares","underlying_shares":11609},"source":{"system":"sec-edgar","filing":"0001645113-22-000093","document":"wf-form4_166750812638914.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000093/wf-form4_166750812638914.xml","form_type":"4"}},{"id":2125609,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2022-11-03T20:42:24.000Z","date":"2022-11-01","kind":"grant","acquired":true,"shares":6830,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted share units that are scheduled to vest in equal installments on each of November 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates."}],"balance_after":50456,"source":{"system":"sec-edgar","filing":"0001645113-22-000093","document":"wf-form4_166750812638914.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000093/wf-form4_166750812638914.xml","form_type":"4"}},{"id":2136324,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2022-10-17T20:35:19.000Z","date":"2022-10-13","kind":"sale","acquired":false,"shares":6754,"price":76.01,"value":513371.54,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."}],"balance_after":43626,"source":{"system":"sec-edgar","filing":"0001645113-22-000086","document":"wf-form4_166603866486448.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000086/wf-form4_166603866486448.xml","form_type":"4"}},{"id":2140380,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2022-10-07T20:16:26.000Z","date":"2022-10-06","kind":"sale","acquired":false,"shares":6754,"price":84.37,"value":569834.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."}],"balance_after":50380,"source":{"system":"sec-edgar","filing":"0001645113-22-000085","document":"wf-form4_166517377413417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000085/wf-form4_166517377413417.xml","form_type":"4"}},{"id":2148666,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2022-09-30T20:20:13.000Z","date":"2022-09-29","kind":"sale","acquired":false,"shares":6754,"price":77.35,"value":522421.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."}],"balance_after":57134,"source":{"system":"sec-edgar","filing":"0001645113-22-000084","document":"wf-form4_166456919628442.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000084/wf-form4_166456919628442.xml","form_type":"4"}},{"id":2151249,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CNS Cancers US"}}],"security":"Ordinary Shares","published_at":"2022-09-26T20:19:35.000Z","date":"2022-09-22","kind":"sale","acquired":false,"shares":6754,"price":77,"value":520058.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."}],"balance_after":63888,"source":{"system":"sec-edgar","filing":"0001645113-22-000083","document":"wf-form4_166422355748808.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000083/wf-form4_166422355748808.xml","form_type":"4"}},{"id":2155704,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2022-09-19T20:10:41.000Z","date":"2022-09-15","kind":"exercise","acquired":false,"shares":5517,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested as of the date hereof."}],"balance_after":5517,"derivative":{"exercise_price":7.15,"expiration_date":"2027-02-21","underlying":"Ordinary Shares","underlying_shares":5517},"source":{"system":"sec-edgar","filing":"0001645113-22-000082","document":"wf-form4_166361822021489.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000082/wf-form4_166361822021489.xml","form_type":"4"}},{"id":2155703,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2022-09-19T20:10:41.000Z","date":"2022-09-15","kind":"sale","acquired":false,"shares":5517,"price":90,"value":496530.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."}],"balance_after":70642,"source":{"system":"sec-edgar","filing":"0001645113-22-000082","document":"wf-form4_166361822021489.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000082/wf-form4_166361822021489.xml","form_type":"4"}},{"id":2155702,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2022-09-19T20:10:41.000Z","date":"2022-09-15","kind":"sale","acquired":false,"shares":6754,"price":87.31,"value":589691.74,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."}],"balance_after":76159,"source":{"system":"sec-edgar","filing":"0001645113-22-000082","document":"wf-form4_166361822021489.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000082/wf-form4_166361822021489.xml","form_type":"4"}},{"id":2155701,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2022-09-19T20:10:41.000Z","date":"2022-09-15","kind":"exercise","acquired":true,"shares":5517,"price":7.15,"value":39446.55,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."}],"balance_after":82913,"source":{"system":"sec-edgar","filing":"0001645113-22-000082","document":"wf-form4_166361822021489.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000082/wf-form4_166361822021489.xml","form_type":"4"}},{"id":2160137,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2022-09-13T20:15:30.000Z","date":"2022-09-08","kind":"sale","acquired":false,"shares":6754,"price":81.48,"value":550315.92,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Amending original Form 4 filed on September 12, 2022 to add additional transaction inadvertently omitted."},{"field":"shares","element":"transactionShares","label":"F2","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."}],"balance_after":77396,"source":{"system":"sec-edgar","filing":"0001645113-22-000081","document":"wf-form4a_166310011170112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000081/wf-form4a_166310011170112.xml","form_type":"4/A","original_submission_date":"2022-09-12"}},{"id":2161252,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2022-09-12T20:32:53.000Z","date":"2022-09-09","kind":"sale","acquired":false,"shares":1863,"price":88,"value":163944.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."}],"balance_after":84150,"source":{"system":"sec-edgar","filing":"0001645113-22-000080","document":"wf-form4_166301475766544.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000080/wf-form4_166301475766544.xml","form_type":"4"}},{"id":2164133,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2022-09-07T20:27:43.000Z","date":"2022-09-06","kind":"sale","acquired":false,"shares":1384,"price":78.57,"value":108740.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."}],"balance_after":86013,"source":{"system":"sec-edgar","filing":"0001645113-22-000079","document":"wf-form4_166258244880634.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000079/wf-form4_166258244880634.xml","form_type":"4"}},{"id":2165636,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2022-09-06T20:19:15.000Z","date":"2022-09-02","kind":"sale","acquired":false,"shares":584,"price":79.037,"value":46157.608,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F14","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units.  This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":87397,"source":{"system":"sec-edgar","filing":"0001645113-22-000074","document":"wf-form4_166249553777247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000074/wf-form4_166249553777247.xml","form_type":"4"}},{"id":2165635,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2022-09-06T20:19:15.000Z","date":"2022-09-01","kind":"sale","acquired":false,"shares":48,"price":78.956,"value":3789.888,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"On September 1, 2022, Mr. Leonard sold 48 shares in multiple trades at prices ranging from $78.70 to $79.28.  The price reported above reflects the weighted average sale price.  Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":87981,"source":{"system":"sec-edgar","filing":"0001645113-22-000074","document":"wf-form4_166249553777247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000074/wf-form4_166249553777247.xml","form_type":"4"}},{"id":2165634,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2022-09-06T20:19:15.000Z","date":"2022-09-01","kind":"sale","acquired":false,"shares":438,"price":78.14,"value":34225.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"On September 1, 2022, Mr. Leonard sold 438 shares in multiple trades at prices ranging from $77.59 to $78.58.  The price reported above reflects the weighted average sale price.  Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":88029,"source":{"system":"sec-edgar","filing":"0001645113-22-000074","document":"wf-form4_166249553777247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000074/wf-form4_166249553777247.xml","form_type":"4"}},{"id":2165633,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2022-09-06T20:19:15.000Z","date":"2022-09-01","kind":"sale","acquired":false,"shares":360,"price":77.062,"value":27742.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"On September 1, 2022, Mr. Leonard sold 360 shares in multiple trades at prices ranging from $76.57 to $77.48.  The price reported above reflects the weighted average sale price.  Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":88467,"source":{"system":"sec-edgar","filing":"0001645113-22-000074","document":"wf-form4_166249553777247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000074/wf-form4_166249553777247.xml","form_type":"4"}},{"id":2165632,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2022-09-06T20:19:15.000Z","date":"2022-09-01","kind":"sale","acquired":false,"shares":240,"price":75.875,"value":18210.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"On September 1, 2022, Mr. Leonard sold 240 shares in multiple trades at prices ranging from $75.42 to $76.41.  The price reported above reflects the weighted average sale price.  Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":88827,"source":{"system":"sec-edgar","filing":"0001645113-22-000074","document":"wf-form4_166249553777247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000074/wf-form4_166249553777247.xml","form_type":"4"}},{"id":2165631,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2022-09-06T20:19:15.000Z","date":"2022-09-01","kind":"sale","acquired":false,"shares":1088,"price":78.678,"value":85601.664,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"On September 1, 2022, Mr. Leonard sold 1,088 shares in multiple trades at prices ranging from $78.46 to $79.28.  The price reported above reflects the weighted average sale price.  Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":89067,"source":{"system":"sec-edgar","filing":"0001645113-22-000074","document":"wf-form4_166249553777247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000074/wf-form4_166249553777247.xml","form_type":"4"}},{"id":2165630,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2022-09-06T20:19:15.000Z","date":"2022-09-01","kind":"sale","acquired":false,"shares":2720,"price":77.917,"value":211934.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"On September 1, 2022, Mr. Leonard sold 2,720 shares in multiple trades at prices ranging from $77.42 to $78.39.  The price reported above reflects the weighted average sale price.  Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":90155,"source":{"system":"sec-edgar","filing":"0001645113-22-000074","document":"wf-form4_166249553777247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000074/wf-form4_166249553777247.xml","form_type":"4"}},{"id":2165629,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2022-09-06T20:19:15.000Z","date":"2022-09-01","kind":"sale","acquired":false,"shares":1750,"price":76.958,"value":134676.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"On September 1, 2022, Mr. Leonard sold 1,750 shares in multiple trades at prices ranging from $76.41 to $77.33.  The price reported above reflects the weighted average sale price.  Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":92875,"source":{"system":"sec-edgar","filing":"0001645113-22-000074","document":"wf-form4_166249553777247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000074/wf-form4_166249553777247.xml","form_type":"4"}},{"id":2165628,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2022-09-06T20:19:15.000Z","date":"2022-09-01","kind":"sale","acquired":false,"shares":1200,"price":75.928,"value":91113.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"On September 1, 2022, Mr. Leonard sold 1,200 shares in multiple trades at prices ranging from $75.41 to $76.31.  The price reported above reflects the weighted average sale price.  Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":94625,"source":{"system":"sec-edgar","filing":"0001645113-22-000074","document":"wf-form4_166249553777247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000074/wf-form4_166249553777247.xml","form_type":"4"}},{"id":2165627,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2022-09-06T20:19:15.000Z","date":"2022-09-01","kind":"sale","acquired":false,"shares":452,"price":78.663,"value":35555.676,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On September 1, 2022, Mr. Leonard sold 452 shares in multiple trades at prices ranging from $78.57 to $78.74.  The price reported above reflects the weighted average sale price.  Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":95825,"source":{"system":"sec-edgar","filing":"0001645113-22-000074","document":"wf-form4_166249553777247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000074/wf-form4_166249553777247.xml","form_type":"4"}},{"id":2165626,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2022-09-06T20:19:15.000Z","date":"2022-09-01","kind":"sale","acquired":false,"shares":2955,"price":78.085,"value":230741.175,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On September 1, 2022, Mr. Leonard sold 2,955 shares in multiple trades at prices ranging from $77.57 to $78.56.  The price reported above reflects the weighted average sale price.  Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":96277,"source":{"system":"sec-edgar","filing":"0001645113-22-000074","document":"wf-form4_166249553777247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000074/wf-form4_166249553777247.xml","form_type":"4"}},{"id":2165625,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2022-09-06T20:19:15.000Z","date":"2022-09-01","kind":"sale","acquired":false,"shares":1914,"price":77.002,"value":147381.828,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On September 1, 2022, Mr. Leonard sold 1,914 shares in multiple trades at prices ranging from $76.54 to $77.42.  The price reported above reflects the weighted average sale price.  Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":99232,"source":{"system":"sec-edgar","filing":"0001645113-22-000074","document":"wf-form4_166249553777247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000074/wf-form4_166249553777247.xml","form_type":"4"}},{"id":2165624,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2022-09-06T20:19:15.000Z","date":"2022-09-01","kind":"sale","acquired":false,"shares":1047,"price":75.935,"value":79503.945,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On September 1, 2022, Mr. Leonard sold 1,047 shares in multiple trades at prices ranging from $75.42 to $76.37.  The price reported above reflects the weighted average sale price.  Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":101146,"source":{"system":"sec-edgar","filing":"0001645113-22-000074","document":"wf-form4_166249553777247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000074/wf-form4_166249553777247.xml","form_type":"4"}},{"id":2195787,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2022-08-03T20:44:02.000Z","date":"2022-08-02","kind":"sale","acquired":false,"shares":414,"price":69.659,"value":28838.826,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.  This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":102193,"source":{"system":"sec-edgar","filing":"0001645113-22-000069","document":"wf-form4_165955941387882.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000069/wf-form4_165955941387882.xml","form_type":"4"}},{"id":2210744,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2022-07-07T21:46:42.000Z","date":"2022-07-05","kind":"grant","acquired":true,"shares":312,"price":59.075,"value":18431.4,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan (\"ESPP\"), for the ESPP purchase period of January 1, 2022 through June 30, 2022.  This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2022."}],"balance_after":102607,"source":{"system":"sec-edgar","filing":"0001645113-22-000060","document":"wf-form4_165723038363274.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000060/wf-form4_165723038363274.xml","form_type":"4"}},{"id":2341832,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2022-03-09T21:55:01.000Z","date":"2022-03-08","kind":"sale","acquired":false,"shares":744,"price":70.1,"value":52154.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units.  This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":102295,"source":{"system":"sec-edgar","filing":"0001645113-22-000029","document":"wf-form4_164686288571914.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000029/wf-form4_164686288571914.xml","form_type":"4"}},{"id":2347762,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2022-03-07T23:14:36.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":4933,"price":80.59,"value":397550.47,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Options to buy 4,933 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates."}],"balance_after":4933,"derivative":{"exercise_price":80.59,"exercise_date":"2023-03-01","expiration_date":"2032-02-29","underlying":"Ordinary Shares","underlying_shares":4933},"source":{"system":"sec-edgar","filing":"0001645113-22-000014","document":"wf-form4_164669485933981.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000014/wf-form4_164669485933981.xml","form_type":"4"}},{"id":2347761,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2022-03-07T23:14:36.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":30422,"price":80.59,"value":2451708.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Options to buy 30,422 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates."}],"balance_after":30422,"derivative":{"exercise_price":80.59,"exercise_date":"2023-03-01","expiration_date":"2032-02-29","underlying":"Ordinary Shares","underlying_shares":30422},"source":{"system":"sec-edgar","filing":"0001645113-22-000014","document":"wf-form4_164669485933981.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000014/wf-form4_164669485933981.xml","form_type":"4"}},{"id":2347760,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2022-03-07T23:14:36.000Z","date":"2022-03-04","kind":"sale","acquired":false,"shares":555,"price":70.407,"value":39075.885,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units.  This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":103039,"source":{"system":"sec-edgar","filing":"0001645113-22-000014","document":"wf-form4_164669485933981.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000014/wf-form4_164669485933981.xml","form_type":"4"}},{"id":2347759,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2022-03-07T23:14:36.000Z","date":"2022-03-03","kind":"sale","acquired":false,"shares":930,"price":74.498,"value":69283.14,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units.  This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":103594,"source":{"system":"sec-edgar","filing":"0001645113-22-000014","document":"wf-form4_164669485933981.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000014/wf-form4_164669485933981.xml","form_type":"4"}},{"id":2347758,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2022-03-07T23:14:36.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":17371,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted share units that are scheduled to vest in equal installments on each of March 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates."}],"balance_after":104524,"source":{"system":"sec-edgar","filing":"0001645113-22-000014","document":"wf-form4_164669485933981.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000014/wf-form4_164669485933981.xml","form_type":"4"}},{"id":2577232,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2021-09-07T20:39:33.000Z","date":"2021-09-02","kind":"sale","acquired":false,"shares":540,"price":138.232,"value":74645.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units.  This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amended total to correct prior mathematical error."}],"balance_after":87153,"source":{"system":"sec-edgar","filing":"0001645113-21-000109","document":"wf-form4_163104715467852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511321000109/wf-form4_163104715467852.xml","form_type":"4"}},{"id":2614850,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2021-08-04T21:20:13.000Z","date":"2021-08-03","kind":"sale","acquired":false,"shares":328,"price":149.43,"value":49013.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units.  This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":89158,"source":{"system":"sec-edgar","filing":"0001645113-21-000098","document":"wf-form4_162811199885199.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511321000098/wf-form4_162811199885199.xml","form_type":"4"}},{"id":2614849,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2021-08-04T21:20:13.000Z","date":"2021-08-02","kind":"sale","acquired":false,"shares":713,"price":149.378,"value":106506.514,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units.  This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":89486,"source":{"system":"sec-edgar","filing":"0001645113-21-000098","document":"wf-form4_162811199885199.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511321000098/wf-form4_162811199885199.xml","form_type":"4"}},{"id":2638088,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Ordinary Shares","published_at":"2021-07-08T21:36:55.000Z","date":"2021-07-06","kind":"grant","acquired":true,"shares":154,"price":137.122,"value":21116.788,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan (\"ESPP\"), for the ESPP purchase period of January 1, 2021 through June 30, 2021.  This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2021."}],"balance_after":90199,"source":{"system":"sec-edgar","filing":"0001645113-21-000088","document":"wf-form4_162578019833894.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511321000088/wf-form4_162578019833894.xml","form_type":"4"}},{"id":2797008,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33977,"kind":"person","name":"Leonard Frank X","position":1,"cik":"0001822879","reported_name":"Leonard Frank X","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Restricted Share Units","published_at":"2021-03-10T21:07:50.000Z","date":"2021-03-08","kind":"sale","acquired":false,"shares":765,"price":130.806,"value":100066.59,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units.  This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":90045,"source":{"system":"sec-edgar","filing":"0001645113-21-000044","document":"wf-form4_161541045494629.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511321000044/wf-form4_161541045494629.xml","form_type":"4"}}],"next_cursor":"2021-03-10T21:07:50.000000Z,2797008"}